Podcast Episode

June 2, 2025

No items found.

15: Prof Craig Ritchie: Looking Back at EPAD, Moving Forward in Alzheimer's Disease

Scott Berry, Ph.D.

President & Senior Statistical Scientist

Scott Berry, Founder of Berry Consultants, interviews Professor Craig Ritchie—specialist in brain health and neurodegenerative diseases, Chief Investigator of EPAD (European Prevention of Alzheimer Dementia), and CEO of Scottish Brain Sciences—for a broad discussion of platform trial methodology in Alzheimer’s Disease research as well as looking towards the future of drug development. The conversation dissects the origins and ambitions of the EPAD initiative, the conception and scientific function of the readiness cohort, and the pragmatic obstacles to deploying innovative trial models within rigid institutional frameworks. Professor Ritchie details why the EPAD platform trial failed to initiate any therapies, explores the fallout and industry shifts following COVID-19, and maps how Scottish Brain Sciences is directly applying these lessons—establishing the IONA readiness cohort to drive integration between clinical research and clinical practice.

Key Highlights

● Systematic review of EPAD’s objectives, specifically the platform trial and the development of a readiness cohort to streamline patient recruitment

● Detailed account of practical barriers that prevented EPAD from launching interventional arms, including pharmaceutical sponsor reluctance, inflexible IMI funding mechanisms, and the inherent risk aversion surrounding novel platform structures

● Discussion of participant contribution to research design and delivery—an early demonstration of patient involvement models now broadly recognized as best practice

● Analysis of COVID-19's dual impact—derailing EPAD's momentum while catalyzing a change in industry and regulatory acceptance of platform trials in drug development

● Tracing the origins and operationalization of the IONA readiness cohort at Scottish Brain Sciences, including direct integration of recruitment, biobanking, and engagement systems to address the translational gap in dementia medicine

● Evidence-based critique of persistent use of conventional clinical trial formats in Alzheimer’s disease, dissecting operational, financial, and data limitations that stall progress

Download PDF

View

Back to All Podcasts

Other Podcast Episodes

View All Podcasts

15: Prof Craig Ritchie: Looking Back at EPAD, Moving Forward in Alzheimer's Disease

June 2, 2025

14: Drug Developers' Lessons from Sports: Regression-to-the-Mean

In this engaging episode of "In the Interim...", host Dr. Scott Berry is joined by Dr. Nick Berry to explore the intriguing parallels between sports and drug development, focusing on the concept of "regression-to-the-mean."

May 26, 2025

13: DSMBs in Adaptive Trials with Roger Lewis

In this episode of "In the Interim…", host Dr. Scott Berry is true to the name of the podcast, as he discusses the unblinded world of adaptive clinical trials alongside Dr. Roger Lewis, a renowned expert in both statistical science and clinical medicine.

May 19, 2025

12: Platform Trial in Psychiatry with Dr. Husseini Manji

In the latest episode of "In the Interim...", Dr. Scott Berry and Dr. Mike Krams sit down with Dr. Husseini Manji, to explore the potential of platform trials in advancing precision medicine within psychiatry, particularly in tackling complex mental illnesses.

May 12, 2025

11: Implementing Adaptive Trials

In Episode 11 of "In the Interim...", host Scott Berry discusses the nuances of implementing adaptive clinical trials with Dr. Anna McGlothlin and Dr. Michelle Detry from Berry Consultants.

May 5, 2025

10: Revisiting Seamless 2/3 Trial for GLP-1 Agonist

In this episode of "In the Interim..." we revisit the ground-breaking seamless phase 2/3 clinical trial for the GLP-1 agonist, dulaglutide—better known as Trulicity.

April 28, 2025

9: I-SPY 2 to GBM AGILE and Beyond

In this episode of "In the Interim...," we sit down with Dr. Meredith Buxton to explore the evolution of platform trials from I-SPY 2 to GBM AGILE and Beyond.

April 21, 2025

8: External Data in Clinical Trials

In this episode of "In the Interim...," Scott Berry and Kert Viele navigate the nuanced debate surrounding the integration of external data in clinical trials.

April 13, 2025

7: Remembering Jimmie Savage

In this episode of "In the Interim," Don Berry shares the life and work of Jimmie Savage, his advisor and a legendary figure in Bayesian statistics.

April 6, 2025

6: The Art and Slog of Innovating

In this compelling episode of "In the Interim," Dr. Mike Krams, a seasoned expert in clinical trials and drug development, joins us to discuss the art and slog of innovation in pharmaceutical companies.

March 31, 2025

5: Religion, Politics, and Ordinal Outcomes

In this episode of "In the Interim," Scott Berry discusses the vital topic of ordinal outcomes in clinical trials—a subject as controversial as politics and religion at the dinner table.

March 24, 2025

4: HEALEY ALS Platform Trial with Dr. Merit Cudkowicz and Dr. Melanie Quintana

In this episode of the podcast, we sit down with Dr. Merit Cudkowicz and Dr. Melanie Quintana to discuss the inception and execution of the Healy ALS Platform Trial, a revolutionary approach designed for efficiency and impactful data collection.

March 17, 2025

3: FACTS 7.1 Release with Tom Parke

In this episode of In the Interim, Berry's Director of Software, Tom Parke, discusses the intricacies and updates surrounding FACTS, a sophisticated clinical trial simulation software.

March 10, 2025

2: When should you use adaptive design clinical trials?

In this episode of "In the Interim," we consider the nuances of adaptive design clinical trials with distinguished guests Dr. Scott Berry and Dr. Kert Viele from Berry Consultants. The conversation centers around the vital question: when should these adaptive designs be implemented?

March 3, 2025

1: The story of Berry Consultants

Discover the transformative journey of Berry Consultants, pioneers in adaptive clinical trials, and their impact on the future of medical research.

February 24, 2025